Heart rate rises most during REM sleep after semaglutide initiation: a matched longitudinal cohort study
- 1Weizmann Institute of Science
Abstract
Study Objectives.Glucagon-like peptide-1 (GLP-1) receptor agonists raise resting heart rate. We asked whether, after semaglutide initiation, the increase is larger during rapid eye movement (REM) sleep than during non-rapid eye movement (NREM) sleep.
Methods.In the Human Phenotype Project, an Israeli cohort of generally healthy adults aged 40 to 70 years, 96 of 494 self-reported semaglutide initiators had a home sleep study (WatchPAT; sleep stages estimated from peripheral arterial tone and actigraphy) before and at least three months after starting. Each was propensity-matched 1:1 to a never-user of GLP-1 drugs measured at the same visits. We estimated the initiators change minus their controls change (difference-in-differences). The REM minus NREM contrast was designated primary after an exploratory analysis.
Results.Relative to controls (90 to 94 pairs), heart rate rose during nocturnal wake (+3.89 beats per minute [bpm], 95% confidence interval 2.35 to 5.44), NREM sleep (+4.82 bpm, 3.12 to 6.52) and REM sleep (+6.25 bpm, 4.42 to 7.91); the REM increase exceeded the NREM increase by 1.42 bpm (0.98 to 1.89). The excess persisted across matching designs and on a relative scale; the proportion of REM sleep did not change. Never-users with similar weight loss showed no REM sleep heart-rate rise (+0.40 bpm, -0.63 to 1.50). Heart-rate variability decreases disappeared after adjustment for heart rate.
Conclusions.Semaglutide initiation was associated with higher heart rate throughout sleep, most during REM sleep, unexplained by weight loss. Clinic measurements may understate this effect. Confirmation with polysomnographic staging is needed.
Graphical Abstract
O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=112 SRC="FIGDIR/small/26365823v1_ufig1.gif" ALT="Figure 1"> View larger version (35K): [email protected]@4dc00aorg.highwire.dtl.DTLVardef@7ae011org.highwire.dtl.DTLVardef@10c7d5c_HPS_FORMAT_FIGEXP M_FIG C_FIG Statement of SignificanceGlucagon-like peptide-1 receptor agonists lower body weight and cardiovascular risk but raise heart rate, an effect usually measured while patients sit awake in a clinic. Whether it differs between sleep stages has not been formally tested. After people started semaglutide, heart rate rose in every sleep stage estimated by a home sleep apnea test, most during rapid eye movement sleep; weight loss did not explain it. A higher sleeping heart rate on a wearable after starting the drug may therefore be an expected effect, not illness. Whether the rise matters for patients with heart disease, in whom rapid eye movement sleep can provoke ischemia and arrhythmia, requires prospective studies with dispensed exposure and electroencephalographic sleep staging.
Related
- No decline in functional status or cognitive function during the first year after treatment initiation for early-stage breast cancer in women aged 75 years and older: a prospective observational matched cohort study
- Body Weight Changes and Exploratory Metabolic Outcomes During Semaglutide and Tirzepatide Treatment: A Real-World Longitudinal Cohort Study from Türkiye
- Weight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort study
- Early-Age alcohol initiation increases the risk of mental disorders in children and adolescents: a longitudinal cohort study
- Cardiometabolic therapy for rhythm control: a case report of refractory atrial fibrillation resolving after initiation of semaglutide for obesity
BibTeX
@misc{krongauz2026heart,
title = {{Heart rate rises most during REM sleep after semaglutide initiation: a matched longitudinal cohort study}},
author = {D. Krongauz and S. Kohn and A. Zulti and Y. Schlesinger and A. Godneva and Y. Talmor-Barkan and E. Segal},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.18.26365823},
url = {https://www.medrxiv.org/content/10.64898/2026.10.18.26365823v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Heart rate rises most during REM sleep after semaglutide initiation: a matched longitudinal cohort study
AU - D. Krongauz
AU - S. Kohn
AU - A. Zulti
AU - Y. Schlesinger
AU - A. Godneva
AU - Y. Talmor-Barkan
AU - E. Segal
PY - 2026
DA - 2026/10/18
PB - medRxiv
DO - 10.64898/2026.10.18.26365823
UR - https://www.medrxiv.org/content/10.64898/2026.10.18.26365823v1
AB - Study Objectives.Glucagon-like peptide-1 (GLP-1) receptor agonists raise resting heart rate. We asked whether, after semaglutide initiation, the increase is larger during rapid eye movement (REM) sleep than during non-rapid eye movement (NREM) sleep. Methods.In the Human Phenotype Project, an Israeli cohort of generally healthy adults aged 40 to 70 years, 96 of 494 self-reported semaglutide initiators had a home sleep study (WatchPAT; sleep stages estimated from peripheral arterial tone and actigraphy) before and at least three months after starting. Each was propensity-matched 1:1 to a never-user of GLP-1 drugs measured at the same visits. We estimated the initiators change minus their controls change (difference-in-differences). The REM minus NREM contrast was designated primary after an exploratory analysis. Results.Relative to controls (90 to 94 pairs), heart rate rose during nocturnal wake (+3.89 beats per minute [bpm], 95% confidence interval 2.35 to 5.44), NREM sleep (+4.82 bpm, 3.12 to 6.52) and REM sleep (+6.25 bpm, 4.42 to 7.91); the REM increase exceeded the NREM increase by 1.42 bpm (0.98 to 1.89). The excess persisted across matching designs and on a relative scale; the proportion of REM sleep did not change. Never-users with similar weight loss showed no REM sleep heart-rate rise (+0.40 bpm, -0.63 to 1.50). Heart-rate variability decreases disappeared after adjustment for heart rate. Conclusions.Semaglutide initiation was associated with higher heart rate throughout sleep, most during REM sleep, unexplained by weight loss. Clinic measurements may understate this effect. Confirmation with polysomnographic staging is needed. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=112 SRC="FIGDIR/small/26365823v1_ufig1.gif" ALT="Figure 1"> View larger version (35K): [email protected]@4dc00aorg.highwire.dtl.DTLVardef@7ae011org.highwire.dtl.DTLVardef@10c7d5c_HPS_FORMAT_FIGEXP M_FIG C_FIG Statement of SignificanceGlucagon-like peptide-1 receptor agonists lower body weight and cardiovascular risk but raise heart rate, an effect usually measured while patients sit awake in a clinic. Whether it differs between sleep stages has not been formally tested. After people started semaglutide, heart rate rose in every sleep stage estimated by a home sleep apnea test, most during rapid eye movement sleep; weight loss did not explain it. A higher sleeping heart rate on a wearable after starting the drug may therefore be an expected effect, not illness. Whether the rise matters for patients with heart disease, in whom rapid eye movement sleep can provoke ischemia and arrhythmia, requires prospective studies with dispensed exposure and electroencephalographic sleep staging.
ER -